Indivior Pharmaceuticals, Inc. issued $500 million in 0.625% Convertible Senior Notes due 2031 on March 17, 2026, with a conversion price of approximately $41.66 per share. The company also prepaid a previous note purchase agreement, terminating it on the same date.